Media

Arterial Network learned for the first time that recently, biopharmaceutical company Worg Pharma, which focuses on providing breakthrough immunotherapy solutions, announced the completion of a new round of financing worth hundreds of millions of yuan. This round of financing is jointly invested by multiple well-known institutions and industry investors, including PICC Capital Equity, Qingsong Capital, and a well-known industry investment institution.

Currently, allergic diseases have become one of the most common chronic diseases worldwide. According to statistics, the prevalence of autoimmune and allergic diseases worldwide exceeds 40%; The number of patients with autoimmune and allergic diseases in China alone exceeds 400 million. Patients with allergic diseases need to take medication for a long time, which brings a heavy social and economic burden. Allergy immunotherapy (AIT) is the only first-line treatment recognized by WHO for allergic diseases. As a global quasi unicorn enterprise in the AIT field, after completing this round of financing, Worg Pharma will accelerate the development and promotion of internationally leading allergy immunotherapy and precision diagnosis solutions in China, benefiting nearly 200 million allergic disease patients in China.

The company's main commercial products include:

Natural extracted allergens SCIT and SLIT (spray) allergy treatment products: covering nearly 40 common allergens, including dust mites, pollen, mold, pet dander, and other allergens.

Molecular allergen allergy treatment products: The world's first developed and commercialized SCIT products for molecular allergens such as mold, cypress, dust mites, etc.

Allergen treatment products: covering over 20 common allergens.

Allergy diagnosis products: 60+allergen skin point testing agents, penicillin allergy detection reagents.

Dr. Xu Aiwu, the founder and chairman of the company, said, "We are very grateful for the strong support of the investors in this round of funding for the company, as well as the trust of the old shareholders. Since its establishment, the company has continuously optimized its business model, iterated product innovation, and is committed to solving clinical pain points. The Chinese allergy market is huge, but product development and promotion are difficult. Baiming plans to enter the Chinese market as soon as possible to provide more convenient, efficient, and safe treatment options for patients. This round of financing will support the global commercial expansion and clinical development of Baimingkang's existing product pipeline, as well as the expansion of emerging markets, while promoting the deepening construction of an international professional management system

The leading investor in this round, PICC Capital Equity, stated that allergic diseases are a significant unmet clinical need, and the field of immune desensitization therapy has huge market prospects. The company has always been committed to providing patients with integrated diagnosis and treatment solutions. Its international operation team not only ensures continuous innovation, but also contributes to the globalization of its products with rich business experience. We look forward to the company developing into a leading enterprise in this niche field, benefiting patients worldwide.

Qingsong Capital, the leading investor in this round, expressed confidence in Worg Pharma innovation capabilities, integrated diagnosis and treatment pipelines, and global team. The company focuses on the research and development of diagnostic and therapeutic products in the field of immune desensitization therapy, and has achieved outstanding results in the development of diagnostic products and drugs for various allergic diseases. The products have shown great market potential. We look forward to the company's continuous innovation in the future, providing more diagnosis and treatment solutions for patients, and with the support of a team with rich commercial experience, achieving global product implementation, contributing more innovative achievements to immune desensitization therapy.